Skip to content (Press Enter)
info@gmbpc.rs
  • Medicinal Products Regulatory Affairs
  • Quality Support
  • Medical devices
  • Food Supplements
  • Cosmetics
  • Biocides Our Services
  • Clinical Support
  • Market Access
  • Supplier Management
  • PMS Support
GMB Pharma Consulting

GMB Pharma Consulting

Consultancy and solutions provider of risk management and compliance services to Life Sciences Industry

  • Who We Are
  • Our Services
    • Medicinal Products Regulatory Affairs
    • Quality Support
    • Medical devices
    • Food Supplements
    • Cosmetics
    • Biocides Our Services
    • Clinical Support
    • Market Access
    • Supplier Management
    • PMS Support
  • Blog
  • Contact Us
GMB Pharma Consulting

GMB Pharma Consulting

Consultancy and solutions provider of risk management and compliance services to Life Sciences Industry

  • Who We Are
  • Our Services
    • Medicinal Products Regulatory Affairs
    • Quality Support
    • Medical devices
    • Food Supplements
    • Cosmetics
    • Biocides Our Services
    • Clinical Support
    • Market Access
    • Supplier Management
    • PMS Support
  • Blog
  • Contact Us
  • Medicinal Products Regulatory Affairs
  • Quality Support
  • Medical devices
  • Food Supplements
  • Cosmetics
  • Biocides Our Services
  • Clinical Support
  • Market Access
  • Supplier Management
  • PMS Support
info@gmbpc.rs

medical devices

2 Results

MDR 2026 Revision: New Expectations for Phthalates and CMR Substances – What Manufacturers Need to Know

•As of 1 January 2026, an important update to the Regulation (EU) 2017/745 (MDR) reinforces how manufacturers must assess hazardous substances in medical devices—especially phthalates, CMR, and endocrine-disrupting substances.This is …

Read More

MIR PDF 7.3.1 (update 23 March 2026)New MIR form – mandatory as from 1st May 2026

•Medical device companies in the EU should take a note:the updated MIR (Manufacturer Incident Report) form version 7.3.1, published on 23 March 2026, becomes mandatory from 1 May 2026. •This …

Read More

Recent Posts

  • EMA Clarifies Rules on Third-Party API Audits: Impact on QP Declarations, EU GMP guide part II, Q3,Q9
  • Da li je vašem biznisu potreban savetnik za hemikalije?
  • MDR 2026 Revision: New Expectations for Phthalates and CMR Substances – What Manufacturers Need to Know
  • BPC Opinion on ethanol (February 2026)
  • EU Cosmetics Regulation Updates 2025–2026: New CMR Restrictions You Can’t Ignore
© Copyright 2026 GMB Pharma Consulting. All Rights Reserved. CoachPress Lite | Developed By Blossom Themes. Powered by WordPress.